PHOXILLUM

Manufacturer: Vantive US Healthcare LLC | Baxter, S.A. de C.V. | Bieffe Medital S.p.A.
Effective date: 2025-05-31
Label type: HUMAN PRESCRIPTION DRUG LABEL
Version: 36
Source: weekly-update
Hydrated at: 2026-07-17 21:45:13

Label at a glance#

ProductPRISMASOL BGK0/2.5

Active ingredientCALCIUM CHLORIDE, MAGNESIUM CHLORIDE, ANHYDROUS DEXTROSE, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, SODIUM PHOSPHATE, DIBASIC

Label structure12 sections

Indications and uses

PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Dosage and administration

Visually inspect PRISMASOL and PHOXILLUM for particulate matter and discoloration prior to administration. Administration should only be under the direction of a physician competent in intensive care treatment including CRRT. Use only with extracorporeal dialysis equipment appropriate for CRRT. The prepared solution is for single patient use only. Aseptic technique should be used throughout administration to the p...

Storage and handling

PRISMASOL and PHOXILLUM solutions are supplied in a two-compartment bag made of polyolefin. The 5000 mL bag is composed of a small compartment (250 mL) and a large compartment (4750 mL). The two compartments are separated by a peel seal. The bag is overwrapped with a transparent overwrap. See Table 2 for the concentrations of the active ingredients in each compartment for each product [see Description (11) ]. Cont...

Contacts and useful links#

PhoneLabel contact1855-857-0003

PhoneFDA MedWatch1-800-FDA-1088

Websitewww.fda.gov

www.fda.gov/medwatch

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Administration Instructions

SPL UNCLASSIFIED SECTION

Visually inspect PRISMASOL and PHOXILLUM for particulate matter and discoloration prior to administration.

Administration should only be under the direction of a physician competent in intensive care treatment including CRRT. Use only with extracorporeal dialysis equipment appropriate for CRRT.

The prepared solution is for single patient use only.

Aseptic technique should be used throughout administration to the patient.

Discard any unused solution.

2.2 Dosing Considerations

SPL UNCLASSIFIED SECTION

PRISMASOL replacement solutions contain 4 different combinations of active ingredients (7 different products with varying ingredient amounts). PHOXILLUM replacement solutions contain 2 different combinations of active ingredients (2 different products with varying ingredient amounts). PRISMASOL and PHOXILLUM are supplied in a two-compartment bag that must be mixed immediately prior to use [see Dosage and Administration (2.3)]:

Small compartment A (250 mL) containing an electrolyte solution, and
Large compartment B (4750 mL) containing the buffer solution.

See Table 1 for the concentrations of the active ingredients (after mixing) in these 9 different replacement solutions (total volume is 5 Liters).

Table 1: Concentrations of Active Ingredients in the 7 PRISMASOL and 2 PHOXILLUM Replacement Solutions after Mixing
	Ca²⁺ ^mEq/L	HCO₃ ^- ^mEq/L	K⁺ ^mEq/L	Mg²⁺ ^mEq/L	Na⁺ ^mEq/L	HPO₄ ^2- ^mmol/L	Cl^- ^mEq/L	Lactate ^mEq/L	Dextrose ^mg/dL	Osmolarity ^mOsm/L
Ca²⁺ = calcium, HCO₃ ^- = bicarbonate, K⁺ = potassium, Mg²⁺ = magnesium, Na⁺ = sodium, HPO₄ ^2- = phosphate, Cl- = chloride; osmolarity is estimated
PRISMASOL Replacement Solutions
BGK0/2.5	2.5	32	0	1.5	140	0	109	3	100	292
BGK4/2.5	2.5	32	4	1.5	140	0	113	3	100	300
BGK2/3.5	3.5	32	2	1	140	0	111.5	3	100	296
BGK2/0	0	32	2	1	140	0	108	3	100	291
B22GK4/0	0	22	4	1.5	140	0	120.5	3	100	296
BGK4/0/1.2	0	32	4	1.2	140	0	110.2	3	100	295
BK0/0/1.2	0	32	0	1.2	140	0	106.2	3	0	282
PHOXILLUM Replacement Solutions
BK4/2.5	2.5	32	4	1.5	140	1	114.5	0	0	294
B22K4/0	0	22	4	1.5	140	1	122	0	0	290

The mode of therapy, solute formulation, flow rates, and length of PRISMASOL and PHOXILLUM replacement therapy in CRRT should be established by a physician based on the patient’s clinical condition, blood concentration of phosphate and other electrolytes, acid-base and glucose balance. Administer either PRISMASOL or PHOXILLUM into the extracorporeal circuit:

Before (pre-dilution) the hemofilter or hemodiafilter,
After (post-dilution) the hemofilter or hemodiafilter, or
Before and after the hemofilter or hemodiafilter.

2.3 Preparing the Solution

SPL UNCLASSIFIED SECTION

Use only if the overwrap is not damaged, all seals are intact, peel seal is not broken, and the solution is clear.

The solution may be warmed to 37°C/98.6°F prior to removing the overwrap to enhance patient comfort. However, only dry heat should be used. Solutions should not be heated in water or in a microwave oven. After heating, verify that the solution remains clear and contains no particulate matter.

The solutions are supplied in two different two-compartment bags made of polyolefin with a peel seal separating compartment A and B (see Figure 1).

Follow the instructions below when connecting the solution bags for correct use of the access ports.

SPL UNCLASSIFIED SECTION

Instructions for preparing solutions supplied in a two-compartment, polyolefin bag with a peel seal:

SPL UNCLASSIFIED SECTION

Figure 2Figure 2	Step 1 Immediately before use, remove the overwrap from the bag and mix the solutions in the two different compartments. After removing the overwrap, inspect the bag for leakage by pressing firmly on the bag. Discard the bag if any leakage is detected since sterility cannot be assured. As soon as the overwrap is removed, the reconstitution of compartments A and B should be done and the mixed solution should be used immediately. After removal of the overwrap, the solution is stable for 24 hours including the duration of the treatment. Hold the small compartment with both hands and squeeze it until an opening is created in the peel seal. (See Figure 2 beside)
Figure 3 Figure 3	Step 2 Squeeze with both hands on the large compartment until the peel seal between the two compartments is entirely open. Shake gently to mix. (See Figure 3 beside) The solution is now ready to use and the bag can be hung on the equipment.
Figure 4aFigure 4a	Step 3 The replacement line may be connected to the bag through either of the luer connector or the injection connector (spike connector). Step 3a The luer connector is a needle-less and swabbable connector. Remove the cap with a twist and pull motion, and connect the male luer lock on the replacement line to the female luer receptor on the bag. (See Figure 4a beside) Ensure that the connection is fully seated and tighten. The connector is now open. Verify that the fluid is flowing freely during use. When the replacement line is disconnected from the luer connector, the connector will close and the flow of the solution will stop.
Figure 4b Figure 4b	Step 3b If the injection connector (spike connector) is used, first remove the snap-off cap. Then introduce the replacement line spike through the swabbable rubber septum of the bag connector. (See Figure 4b beside) Ensure that the spike is fully inserted and verify that the fluid is flowing freely during use.

2.4 Adding Drugs to the Solutions

SPL UNCLASSIFIED SECTION

After mixing, additional drugs may be added to the bag via injection connector (spike connector) in large compartment B. In general, administer drugs other than phosphate through a different access line.

When introducing drugs, use aseptic techniques and mix thoroughly prior to connecting the solution bag to the extracorporeal circuit.

Do not use if there is a color change and/or the appearance of precipitates, insoluble complexes or crystals after addition of medication.

Phosphate: Up to 1.2 mmol/L of phosphate can be added to the bag as potassium phosphate or sodium phosphate. The total potassium concentration of PRISMASOL solution should not exceed 4 mEq/L. Use sodium phosphate to add phosphate if the total potassium concentration in PRISMASOL solution is 4 mEq/L.

SPL UNCLASSIFIED SECTION

PHOXILLUM Solutions:

Phosphate: Phosphate up to 0.2 mmol/L may be added to the solution. Use sodium phosphate if adding phosphate to bag. The total phosphate concentration should not exceed 1.2 mmol/L.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

See Table 1 for the concentrations of the active ingredients (after mixing) in these 9 different replacement solutions [see Dosage and Administration (2.2)].

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products.

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Electrolyte and Volume Abnormalities

SPL UNCLASSIFIED SECTION

PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately [see Dosage and Administration (2) ].

PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

5.2 Blood Glucose Abnormalities

SPL UNCLASSIFIED SECTION

The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following adverse reactions have been identified during postapproval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Metabolic acidosis
Hypotension
Acid-base disorders
Electrolyte imbalance including calcium ionized increased (reported in PRISMASOL solutions containing calcium), hyperphosphatemia, and hypophosphatemia
Fluid imbalance

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

As with the use of other replacement solutions, blood concentrations of dialyzable drugs may be reduced by CRRT due to their removal by the hemofilter or hemodiafilter. The blood concentrations of certain drugs may need to be monitored and appropriate therapy implemented to correct for removal during treatment.

7.1 Citrate

SPL UNCLASSIFIED SECTION

When used as an anticoagulant, citrate contributes to the overall buffer load and can reduce plasma calcium levels. Select the PRISMASOL/PHOXILLUM formulation(s) accordingly.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

RISKS

PRISMASOL and PHOXILLUM are pharmacologically inactive solutions. While there are no adequate and well controlled studies in pregnant women, appropriate administration of PRISMASOL and PHOXILLUM solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. Animal reproduction studies have not been conducted with PRISMASOL and PHOXILLUM solutions.

The estimated background risk of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

SPL UNCLASSIFIED SECTION

Maintenance of normal acid-base balance is important for fetal well-being.

8.2 Lactation

LACTATION SECTION

Risk Summary

RISKS

The components of PRISMASOL and PHOXILLUM solutions are excreted in human milk. Appropriate administration of PRISMASOL and PHOXILLUM solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness have been established based on published clinical data of CRRT replacement solutions with compositions similar to PRISMASOL and PHOXILLUM used in adults and two hemofiltration studies in pediatric patients, including a study of newborns to 17 years old.

8.5 Geriatric Use

GERIATRIC USE SECTION

The experience with PRISMASOL and PHOXILLUM solutions in geriatric patients has not identified novel concerns.

11 DESCRIPTION

DESCRIPTION SECTION

PRISMASOL and PHOXILLUM solutions are clear, sterile, free of bacterial endotoxins and contain no bacteriostatic or antimicrobial agents. These solutions are used in Continuous Renal Replacement Therapies (CRRT) as a replacement solution in hemofiltration and hemodiafiltration. Depending on the product (see Table 2), the two compartments contain:

Calcium chloride, USP, is chemically designated calcium chloride dihydrate (CaCl₂ • 2H₂O).

Magnesium chloride, USP, is chemically designated magnesium chloride hexahydrate (MgCl₂ • 6H₂O).

Sodium chloride, USP, is chemically designated NaCl.

Potassium chloride, USP, is chemically designated KCl.

Sodium bicarbonate, USP, is chemically designated NaHCO₃.

Dextrose, USP, is chemically designated D-Glucose anhydrous (C₆H₁₂O₆) or D-Glucose monohydrate (C₆H₁₂O₆ • H₂O).

Lactic acid, USP, is chemically designated CH₃CH(OH)COOH.

Dibasic sodium phosphate, USP, is chemically designated as disodium hydrogen phosphate, dihydrate (Na₂HPO₄ • 2H₂O)

Table 2 - Compartment Composition (Before Mixing)
	Compartment A (g/L)				Compartment B (g/L)
	Calcium Chloride ∙ 2H₂O	Magnesium Chloride ∙ 6H₂O	Dextrose anhydrous (as monohydrate)	Lactic Acid	Sodium Chloride	Sodium bicarbonate	Potassium Chloride	Sodium Phosphate ∙ 2H₂O
PRISMASOL SOLUTIONS
BGK 0/2.5	3.68	3.05	20 (22)	5.40	6.46	3.09	0	0
BGK 4/2.5	3.68	3.05	20 (22)	5.40	6.46	3.09	0.314	0
BGK 2/3.5	5.15	2.03	20 (22)	5.40	6.46	3.09	0.157	0
BGK 2/0	0	2.03	20 (22)	5.40	6.46	3.09	0.157	0
B22GK 4/0	0	3.05	20 (22)	5.40	7.07	2.21	0.314	0
BK 0/0/1.2	0	2.44	0 (0)	5.40	6.46	3.09	0	0
BGK 4/0/1.2	0	2.44	20 (22)	5.40	6.46	3.09	0.314	0
PHOXILLUM SOLUTIONS
BK 4/2.5	3.68	3.05	0 (0)	0	6.34	3.09	0.314	0.187
B22K 4/0	0	3.05	0 (0)	0	6.95	2.21	0.314	0.187

The pH of the final solution is in the range of 7.0 to 8.5.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

PRISMASOL and PHOXILLUM solutions are pharmacologically inactive. The electrolyte concentrations in the solutions are chosen to restore plasma levels to clinically desired concentrations or maintain plasma levels at the desired concentrations.

PRISMASOL and PHOXILLUM solutions are used as replacement solution to replace water and electrolytes removed during hemofiltration and hemodiafiltration. Bicarbonate (or precursor lactate) in the solution is used as an alkalinizing buffer to restore acid-base balance to a clinically desirable level.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

The distribution of electrolytes, bicarbonate, and dextrose is determined by the patient's clinical condition, metabolic status, and residual renal function.

The elimination and replacement of water, electrolytes and buffer depend on the patient's electrolyte and acid-base balance, metabolic status, residual renal function and ongoing physiologic losses through intestinal, respiratory and cutaneous routes.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

The bag is overwrapped with a transparent overwrap. See Table 2 for the concentrations of the active ingredients in each compartment for each product [see Description (11)].

Container	Fill Volume	NDC
PRISMASOL Solutions
PRISMASOL BGK0/2.5	5000 mL	24571-108-06
PRISMASOL BGK4/2.5	5000 mL	24571-105-06
PRISMASOL BGK2/3.5	5000 mL	24571-103-06
PRISMASOL BGK2/0	5000 mL	24571-102-06
PRISMASOL B22GK4/0	5000 mL	24571-111-06
PRISMASOL BK0/0/1.2	5000 mL	24571-113-06
PRISMASOL BGK4/0/1.2	5000 mL	24571-114-06
PHOXILLUM Solutions
PHOXILLUM BK4/2.5	5000 mL	24571-116-06
PHOXILLUM B22K4/0	5000 mL	24571-117-06

Not all formulations may be marketed.

STORAGE AND HANDLING SECTION

Storage conditions

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF). [See USP Controlled Room Temperature]

Do not freeze or expose to excessive heat. Do not use if precipitate has formed or if container seals have been damaged.

Manufactured for:
Vantive US Healthcare LLC
Deerfield, Illinois 60015

07-19-00-9693

Vantive, Phoxillum and PrismaSol are trademarks of Vantive Health LLC, or its affiliates

Package/Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-108-06

OK⁺
mEq/L

2.5 Ca²⁺
mEq/L

PrismaSol BGK0/2.5
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)	A	B
Calcium chloride • 2H₂O	3.68
Magnesium chloride • 6H₂O	3.05
Dextrose anhydrous	20.0
(as dextrose monohydrate)	22.0
Sodium chloride		6.46
Lactic acid	5.40
Sodium bicarbonate		3.09
Water for injections q.s, Carbon dioxide for pH adjustment

A
250 mL

B
4750 mL

After reconstitution, A + B
	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Lactate C₃H₅O₃ ^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Dextrose
mmol/L	1.25	0.75	140	109.0	3.0	32	0	5.5
mEq/L	2.5	1.5	140	109.0	3.0	32	0	(100 mg/dL)
Theoretical osmolarity: 292 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091613
Product # 110240

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5278

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-105-06

4K⁺
mEq/L

2.5 Ca²⁺
mEq/L

PrismaSol BGK4/2.5
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)	A	B
Calcium chloride • 2H₂O	3.68
Magnesium chloride • 6H₂O	3.05
Dextrose anhydrous	20.0
(as dextrose monohydrate)	22.0
Sodium chloride		6.46
Potassium chloride		0.314
Lactic acid	5.40
Sodium bicarbonate		3.09
Water for injections q.s, Carbon dioxide for pH adjustment

A
250 mL

B
4750 mL

After reconstitution, A + B
	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Lactate C₃H₅O₃ ^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Dextrose
mmol/L	1.25	0.75	140	113.0	3.0	32	4.0	5.5
mEq/L	2.5	1.5	140	113.0	3.0	32	4.0	(100 mg/dL)
Theoretical osmolarity: 300 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091637
Product # 110242

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy
07-25-00-5280

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-103-06

2K⁺
mEq/L

3.5 Ca²⁺
mEq/L

PrismaSol BGK2/3.5
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)	A	B
Calcium chloride • 2H₂O	5.15
Magnesium chloride • 6H₂O	2.03
Dextrose anhydrous	20.0
(as dextrose monohydrate)	22.0
Sodium chloride		6.46
Potassium chloride		0.157
Lactic acid	5.40
Sodium bicarbonate		3.09
Water for injections q.s, Carbon dioxide for pH adjustment

Rx only
A
250 mL

B
4750 mL

After reconstitution, A + B
	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Lactate C₃H₅O₃ ^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Dextrose
mmol/L	1.75	0.5	140	111.5	3.0	32	2.0	5.5
mEq/L	3.5	1.0	140	111.5	3.0	32	2.0	(100 mg/dL)
Theoretical osmolarity: 296 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091644
Product # 110243

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy
07-25-00-5281

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-102-06

2K⁺
mEq/L

0Ca²⁺
mEq/L

PrismaSol BGK2/0
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)	A	B
Magnesium chloride • 6H₂O	2.03
Dextrose anhydrous	20.0
(as dextrose monohydrate)	22.0
Sodium chloride		6.46
Potassium chloride		0.157
Lactic acid	5.40
Sodium bicarbonate		3.09
Water for injections q.s, Carbon dioxide for pH adjustment

A
250 mL

B
4750 mL

After reconstitution, A + B
	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Lactate C₃H₅O₃ ^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Dextrose
mmol/L	0	0.5	140	108.0	3.0	32	2.0	5.5
mEq/L	0	1.0	140	108.0	3.0	32	2.0	(100 mg/dL)
Theoretical osmolarity: 291 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091651
Product # 110244

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5282

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-111-06

4K⁺
mEq/L

Bicarbonate 22

0Ca²⁺
mEq/L

PrismaSol B22GK4/0
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)	A	B
Magnesium chloride • 6H₂O	3.05
Dextrose anhydrous	20.0
(as dextrose monohydrate)	22.0
Sodium chloride		7.07
Potassium chloride		0.314
Lactic acid	5.40
Sodium bicarbonate		2.21
Water for injections q.s, Carbon dioxide for pH adjustment

A
250 mL

B
4750 mL

After reconstitution, A + B
	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Lactate C₃H₅O₃ ^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Dextrose
mmol/L	0	0.75	140	120.5	3.0	22	4.0	5.5
mEq/L	0	1.5	140	120.5	3.0	22	4.0	(100 mg/dL)
Theoretical osmolarity: 296 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414116781
Product # 115001

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5285

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-113-06

0K⁺
mEq/L

0Ca²⁺
mEq/L

PrismaSol BK0/0/1.2
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)	A	B
Magnesium chloride • 6H₂O	2.44
Sodium chloride		6.46
Lactic acid	5.40
Sodium bicarbonate		3.09
Water for injections q.s, Carbon dioxide for pH adjustment

A
250 mL

B
4750 mL

After reconstitution, A + B
	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Lactate C₃H₅O₃ ^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Dextrose
mmol/L	0	0.6	140	106.2	3.0	32	0	0
mEq/L	0	1.2	140	106.2	3.0	32	0	(0 mg/dL)
Theoretical osmolarity: 282 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091309
Product # 110239

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5277

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Barcode
NDC# 24571-114-06

4K⁺
mEq/L

0Ca²⁺
mEq/L

PrismaSol BGK4/0/1.2
Rx only
Barcode
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution each 1000 mL contains (g)	A	B
Magnesium chloride • 6H₂O	2.44
Dextrose anhydrous	20.0
(as dextrose monohydrate)	22.0
Sodium chloride		6.46
Potassium chloride		0.314
Lactic acid	5.40
Sodium bicarbonate		3.09
Water for injections q.s, Carbon dioxide for pH adjustment

A
250 mL

B
4750 mL

After reconstitution, A + B
	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Lactate C₃H₅O₃ ^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Dextrose
mmol/L	0	0.6	140	110.2	3.0	32	4.0	5.5
mEq/L	0	1.2	140	110.2	3.0	32	4.0	(100 mg/dL)
Theoretical osmolarity: 295 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.
See package insert for dosage information and

further instructions.

Sterile and free from bacterial endotoxins.

Confirm the integrity of the packaging. Use only if

solution is clear. For single use only.

DISCARD ANY UNUSED SOLUTION.

Store at +20°C to +25°C (+68°F to +77°F); excursions

permitted to +15°C to +30°C (+59°F to

+86°F). [See USP Controlled room Temperature.]

Do not freeze or expose to excessive heat.

As soon as the overwrap is removed, the reconstitution

of compartments A and B should be done

and the reconstituted solution should be used immediately.

After removal of the overwrap, the solution

is stable for 24 hours including the duration of

the treatment. Mix additives BEFORE connecting

this bag to the extracorporeal circuit. (See insert

for further information.) This product is not made

with natural rubber latex.

5000 mL
EAN-14: 07332414091620
Product # 110241

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-5279

Mixing steps
① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Compartment B

Barcode
NDC# 24571-116-06

4K⁺
mEq/L

1 Phosphate
mmol/L

2.5 Ca²⁺
mEq/L

Phoxillum BK4/2.5
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution, each 1000 mL contains (g):	A	B
Calcium chloride • 2H₂O	3.68
Magnesium chloride • 6H₂O	3.05
Sodium chloride		6.34
Potassium chloride		0.314
Sodium bicarbonate		3.09
Dibasic sodium phosphate • 2H₂O		0.187
Water for injections q.s

Rx only
A
250 mL

B
4750 mL

After reconstitution, A + B

	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Phosphate HPO₄ ^2-	Dextrose
mmol/L	1.25	0.75	140	114.5	32	4.0	1	0
mEq/L	2.5	1.5	140	114.5	32	4.0	(1 mmol/L)	(0 mg/dL)

Theoretical osmolarity: 294 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.
See package insert for dosage information and further instructions. Sterile and free from bacterial endotoxins.
Confirm the integrity of the packaging. Use only if solution is clear. For single use only. DISCARD ANY UN-
USED SOLUTION. Store at +20ºC to +25ºC (+68ºF to +77ºF); excursions permitted to +15ºC - +30ºC (+59ºF
to +86ºF). [See USP Controlled Room Temperature]. Do not freeze or expose to excessive heat. As soon as the
overwrap is removed, the reconstitution of compartments A and B should be done and the reconstituted
solution should be used immediately. After removal of the overwrap, the solution is stable for 24 hours including the duration of the treatment. Mix additives BEFORE connecting this bag to the extracorporeal circuit. (See insert for
further information). This product is not made with natural rubber latex. Carbon dioxide and hydrochloric
acid or diluted hydrochloric acid added for pH adjustment.

5000 mL
EAN-14: 07332414116040
Product # 114905

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-6254

Mixing steps

① SQUEEZE TOP corners to break seal

② Squeeze BAG SIDES to fully open seal

Compartment B

Barcode
NDC# 24571-117-06

4K⁺
mEq/L

0 Ca²⁺
mEq/L

22 Bicarbonate
mEq/L

1 Phosphate
mmol/L

Phoxillum B22K4/0
Replacement Solution for Continuous Renal Replacement Therapy

Before reconstitution, each 1000 mL contains (g):	A	B
Magnesium chloride • 6H₂O	3.05
Sodium chloride		6.95
Potassium chloride		0.314
Sodium bicarbonate		2.21
Dibasic sodium phosphate • 2H₂O		0.187
Water for injections q.s

Rx only
A
250 mL

B
4750 mL

After reconstitution, A + B

	Calcium Ca²⁺	Magnesium Mg²⁺	Sodium Na⁺	Chloride Cl^-	Bicarbonate HCO₃ ^-	Potassium K⁺	Phosphate HPO₄ ^2-	Dextrose
mmol/L	0	0.75	140	122.0	22	4.0	1	0
mEq/L	0	1.5	140	122.0	22	4.0	(1 mmol/L)	(0 mg/dL)

Theoretical osmolarity: 290 mOsm/L pH: 7.0 – 8.5

Mix both compartments before use.

See package insert for dosage information and further instructions. Sterile and free from bacterial endotoxins.
Confirm the integrity of the packaging. Use only if solution is clear. For single use only. DISCARD ANY UN-
USED SOLUTION. Store at +20°C to +25°C (+68°F to +77°F); excursions permitted to +15°C to +30°C (+59°F
to +86°F). [See USP Controlled Room Temperature]. Do not freeze or expose to excessive heat. As soon as the
overwrap is removed, the reconstitution of compartments A and B should be done and the reconstituted solution
should be used immediately. After removal of the overwrap, the solution is stable for 24 hours including the duration
of the treatment. Mix additives BEFORE connecting this bag to the extracorporeal circuit. (See insert for
further information). This product is not made with natural rubber latex. Carbon dioxide and hydrochloric or diluted hydrochloric acid added for pH adjustment.

5000 mL
EAN-14: 07332414116057
Product # 114906

VANTIVE Logo

Batch No. and expiry date are printed on the back of the bag.
Manufactured for:
Vantive US Healthcare LLC
Deerfield IL 60015 USA
Made in Italy

REPLACEMENT
Solution for Continuous Renal Replacement Therapy

07-25-00-6255

Product Linked Resources#

Resource, Code type, Value table
Resource	Code type	Value	Source image
Data code	Code 128	2457110206	image-09.JPG.jpg
Data code	Code 128	2457110806	image-06.JPG.jpg
Data code	Code 128	2457111706	image-14.jpg
Data code	Data Matrix	110239	image-11.JPG.jpg
Data code	Data Matrix	110240	image-06.JPG.jpg
Data code	Data Matrix	110241	image-12.JPG.jpg
Data code	Data Matrix	110242	image-07.JPG.jpg
Data code	Data Matrix	110243	image-08.JPG.jpg
Data code	Data Matrix	110244	image-09.JPG.jpg
Data code	Data Matrix	114905	image-13.jpg
Data code	Data Matrix	114906	image-14.jpg
Data code	Data Matrix	115001	image-10.JPG.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
6e3c022f-0786-43f1-8857-edff89d5153f	Product name	1	20260309
9e37788c-b1bf-42ae-aac9-b60601606144	Product name	8	20260122
95250459-30e4-45c1-b08a-993044f49109	Product name	2	20250805
d9771140-739b-484b-ae64-b79528ff1211	Product name	3	20250801
bee4fa8d-8d82-423a-a0b5-40a89dd13a99	Product name	1	20250618
e0d2eb29-08bd-4bba-90d1-c91c68a38767	Product name	4	20250516
efd58dcf-540a-4531-8766-e713129ca6f2	Product name	1	20250307
30b0ac6e-02aa-0e5c-0d8b-cffdf3a282b2	Product name	5	20250304
4b7700e3-6e0e-45e5-9d22-6f754d61386e	Product name	2	20250304
726062af-1135-4707-a1d7-57256991bbf9	Product name	2	20250226
1527ac37-808d-43be-a63e-74e1258dbe46	Product name	9	20250219
a21a21e5-f36d-4c1f-8918-def921b8f7e3	Product name	3	20250124
bed0530e-f939-4541-956b-6928a2f6404f	Product name	1	20241008
cefa60e2-a5b5-493e-9c54-24735b7dc509	Product name	6	20240814
fb7ab793-2c12-4079-b100-a64f73bef25a	Product name	4	20240712
334fe8d2-68fb-4331-a576-420e302ec069	Product name	7	20240320
efd58652-cb8f-4018-91ca-4b0eb2ff729f	Product name	7	20240226
362d7abb-94e6-4c60-9a58-266894157713	Product name	1	20231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7	Product name	2	20230717
cb89b86a-369e-4204-8910-ae797c503af3	Product name	1	20230706
dc7c5daa-021f-40dd-b00d-63982cb2067a	Product name	1	20230426
9fcb7a91-de07-4f00-aabf-e4d6fda403d5	Product name	8	20230322
e2db08c6-133f-4f4f-afb4-e90a2418d6f6	Product name	1	20230320
6bd95106-a412-1dad-b9cc-4cb74bfb27ce	Product name	2	20230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7	Product name	2	20211025
9badc7be-250a-44ab-aa36-926af3f02679	Product name	1	20210527
2641ccb3-721d-4fbf-9f2f-ca2f18157a62	Product name	3	20210309
f52be47f-7aa7-46c0-b1fa-50c18dd50206	Product name	1	20201029
08ffbcbf-26df-b99c-1dab-64fc4cfae89f	Product name	5	20200925
e4870509-7e28-6f92-f0be-dd3dd889a9cf	Product name	5	20200810
0ec3537a-6c9b-432a-896c-b9ea8723049a	Product name	9	20200701
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cd	Product name	2	20190619
444b3e50-f226-46ef-bfca-2e7035d140cd	Product name	1	20190611
816b97af-edc5-4060-aff1-b814bdbcad50	Product name	1	20190415
e92765c1-be81-432a-b909-1b10777ec378	Product name	1	20190208
11ed6f83-cdd2-4637-8379-b1a1d3ae3cde	Product name	1	20181101
d4880ace-a516-8c47-8dfd-73a4ba5887d7	Product name	2	20180830
7cda52fc-125f-421c-8fea-bc1974370c49	Product name	2	20180703
7916de40-e296-41f0-b811-6d0df1a33e2c	Product name	9	20180627
86c45a79-b9f0-4476-a27c-6e10db098497	Product name	1	20180125
cefa60e2-a5b5-493e-9c54-24735b7dc509	Product name	2	20171212
419aab54-5d5a-4146-9453-026d4a9991be	Product name	2	20170525
26acd337-b838-40ac-bcbc-05c3b81c8712	Product name	1	20170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89f	Product name	2	20160823
d5e51f11-ad28-caa4-4b49-4143974782ad	Product name	1	20150831
290f523a-f9db-9774-b5a9-e1f908ac1782	Product name	1	20150828
e7e58cd3-cacb-49df-8d34-1ee335614abb	Product name	1	20150609
0ca1d589-929b-4b33-bc5b-1d84abdafa6a	Product name	1	20150324
fc363c46-397b-4476-ac0f-70e43e8e4592	Product name	1	20150324
0441a8f5-3835-497c-aedd-bc78cba56b2a	Product name	1	20150317
89dac932-b90a-4410-9ab1-84c53e57de25	Product name	1	20150316
19c71a3d-ed9c-166b-a7e5-38c250c35631	Product name	1	20140508
5668b646-cd56-c3c7-bdea-3f6b1a8840db	Product name	1	20140508
597b1cfd-7b31-5048-62be-ca5cd740da2f	Product name	1	20140508
684ea482-2e8b-14af-5664-b98f1e402036	Product name	1	20140508
810ab97e-f109-f41c-7c83-6a652a9cbf43	Product name	1	20140508
87711080-88eb-65c5-b2dd-bf99e700a372	Product name	1	20140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2dd	Product name	1	20140508
b060cc1a-fe47-856b-0b77-4448b5963de8	Product name	1	20140508
c6b65c52-69c7-df49-550a-a50c137f6218	Product name	1	20140508
ec2149b3-5c6d-5344-f757-c86411073075	Product name	1	20140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
24571-102-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-102-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-102-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-102-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-103-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-103-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-103-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-103-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-105-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-105-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-105-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-105-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-108-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-108-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-108-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-108-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-111-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-111-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-111-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-111-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-113-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-113-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-113-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-113-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-114-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-114-05	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-114-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-114-06	2021-08-03	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-102-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-102-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-102-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-102-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-103-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-103-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-103-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-103-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-105-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-105-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-105-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-105-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-108-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-108-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-108-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-108-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-111-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-111-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-111-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-111-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-113-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-113-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-113-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-113-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-114-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-114-05	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-114-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015
24571-114-06	2021-07-23	C162847	48780-1	c7ccaba7-157e-fd44-e053-dadaa90aa01b	These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and PHOXILLUM. PRISMASOL renal replacement solution PRISMASOL Initial U.S. Approval: 2006 PHOXILLUM renal replacement solution PHOXILLUM Initial U.S. Approval: 2015

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
24571-108-05	ML - Milliliter	24571-108	ab6b2d84-acc4-4f9f-a061-207d6ed87e3c	1	2012-07-24
24571-108-06	ML - Milliliter	24571-108	95318427-e79d-48d0-b2fc-7cc1cf92067e	1	2019-06-19
24571-105-05	ML - Milliliter	24571-105	b1124d3d-e043-4b45-a274-39141cf042f4	1	2012-07-24
24571-105-06	ML - Milliliter	24571-105	b94f6e77-f8aa-4b1c-a025-18029065c4b8	1	2019-06-19
24571-103-05	ML - Milliliter	24571-103	86f5d915-30dc-436c-9f09-3cb7f9f6b133	1	2012-07-24
24571-103-06	ML - Milliliter	24571-103	24c083ac-1468-4289-b9a6-0a8ed979b87b	1	2016-05-16
24571-102-05	ML - Milliliter	24571-102	094d32ef-40d4-489f-8323-a57db2328b8c	1	2012-07-24
24571-102-06	ML - Milliliter	24571-102	830f699a-367e-489a-bf47-a02430ef8b9d	1	2016-05-16
24571-111-05	ML - Milliliter	24571-111	c54d1bc5-7a6e-4aea-98af-ecb3d22695fa	1	2012-07-24
24571-111-06	ML - Milliliter	24571-111	47056515-0056-41cd-bfbd-15b59cb4ed05	1	2016-05-16
24571-113-05	ML - Milliliter	24571-113	fc776e59-a5bd-417e-8b6a-e8d9f602b267	1	2012-07-24
24571-113-06	ML - Milliliter	24571-113	eca6c825-f19f-4bcb-9327-22cb736211b4	1	2019-06-19
24571-114-05	ML - Milliliter	24571-114	36d45986-24c2-4282-acf5-82035fd9e34b	1	2012-07-24
24571-114-06	ML - Milliliter	24571-114	7ba66bd2-3f80-418d-9a79-311ab70ec3bb	1	2021-01-08
24571-116-05	ML - Milliliter	24571-116	5e0ffb8e-499f-40f0-b3af-fcc86cbb5ae1	1	2016-05-16
24571-116-06	ML - Milliliter	24571-116	5e8de6b2-e0aa-4c65-86b7-98e2978be752	1	2021-05-05
24571-117-06	ML - Milliliter	24571-117	26c586e2-5766-4704-b456-69cc61f9c3c4	1	2020-09-14

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
Calcium Chloride	ACTIVE INGREDIENT	M4I0D6VV5M	10
Dextrose monohydrate	ACTIVE INGREDIENT	LX22YL083G	10
Lactic Acid	ACTIVE INGREDIENT	33X04XA5AT	10
Magnesium Chloride	ACTIVE INGREDIENT	02F3473H9O	10
Potassium Chloride	ACTIVE INGREDIENT	660YQ98I10	10
Sodium Bicarbonate	ACTIVE INGREDIENT	8MDF5V39QO	10
Sodium Chloride	ACTIVE INGREDIENT	451W47IQ8X	10
Anhydrous Dextrose	ACTIVE MOIETY	5SL0G7R0OK	10
Bicarbonate Ion	ACTIVE MOIETY	HN1ZRA3Q20	10
Chloride Ion	ACTIVE MOIETY	Q32ZN48698	10
Lactic Acid	ACTIVE MOIETY	33X04XA5AT	10
Carbon Dioxide	INACTIVE INGREDIENT	142M471B3J	10
Water	INACTIVE INGREDIENT	059QF0KO0R	10

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 33 matching rows.

PRISMASOL BGK0/2.5
calcium chloride, magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, and sodium bicarbonate
CALCIUM CHLORIDE
CALCIUM CATION
CHLORIDE ION
MAGNESIUM CHLORIDE
MAGNESIUM CATION
ANHYDROUS DEXTROSE
LACTIC ACID
SODIUM CHLORIDE
SODIUM CATION
SODIUM BICARBONATE
BICARBONATE ION
WATER
CARBON DIOXIDE
PRISMASOL BGK4/2.5
calcium chloride, magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride
POTASSIUM CHLORIDE
POTASSIUM CATION
PRISMASOL BGK2/3.5
PRISMASOL BGK2/0
magnesium chloride, dextrose anhydrous, lactic acid, sodium chloride, sodium bicarbonate, and potassium chloride
PRISMASOL B22GK4/0
PRISMASOL BK0/0/1.2
magnesium chloride, lactic acid, sodium chloride, and sodium bicarbonate
PRISMASOL BGK4/0/1.2
PHOXILLUM BK4/2.5
calcium chloride, magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride, and sodium phosphate dibasic dihydrate
SODIUM PHOSPHATE, DIBASIC
PHOSPHATE ION
HYDROCHLORIC ACID
PHOXILLUM B22K4/0
magnesium chloride, sodium chloride, sodium bicarbonate, potassium chloride, and sodium phosphate dibasic dihydrate

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
24571-108	24571-108-06
24571-105	24571-105-06
24571-103	24571-103-06
24571-102	24571-102-06
24571-111	24571-111-06
24571-113	24571-113-06
24571-114	24571-114-06
24571-116	24571-116-06
24571-117	24571-117-06

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 2 · 73 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
CALCIUM CHLORIDE	M4I0D6VV5M	ACTIB
MAGNESIUM CHLORIDE	02F3473H9O	ACTIB
ANHYDROUS DEXTROSE	5SL0G7R0OK	ACTIB
LACTIC ACID	33X04XA5AT	ACTIB
SODIUM CHLORIDE	451W47IQ8X	ACTIB
SODIUM BICARBONATE	8MDF5V39QO	ACTIB
WATER	059QF0KO0R	IACT
CARBON DIOXIDE	142M471B3J	IACT
CALCIUM CHLORIDE	M4I0D6VV5M	ACTIB
MAGNESIUM CHLORIDE	02F3473H9O	ACTIB
ANHYDROUS DEXTROSE	5SL0G7R0OK	ACTIB
LACTIC ACID	33X04XA5AT	ACTIB
SODIUM CHLORIDE	451W47IQ8X	ACTIB
SODIUM BICARBONATE	8MDF5V39QO	ACTIB
POTASSIUM CHLORIDE	660YQ98I10	ACTIB
WATER	059QF0KO0R	IACT
CARBON DIOXIDE	142M471B3J	IACT
CALCIUM CHLORIDE	M4I0D6VV5M	ACTIB
MAGNESIUM CHLORIDE	02F3473H9O	ACTIB
ANHYDROUS DEXTROSE	5SL0G7R0OK	ACTIB
LACTIC ACID	33X04XA5AT	ACTIB
SODIUM CHLORIDE	451W47IQ8X	ACTIB
SODIUM BICARBONATE	8MDF5V39QO	ACTIB
POTASSIUM CHLORIDE	660YQ98I10	ACTIB
WATER	059QF0KO0R	IACT
CARBON DIOXIDE	142M471B3J	IACT
MAGNESIUM CHLORIDE	02F3473H9O	ACTIB
ANHYDROUS DEXTROSE	5SL0G7R0OK	ACTIB
LACTIC ACID	33X04XA5AT	ACTIB
SODIUM CHLORIDE	451W47IQ8X	ACTIB
SODIUM BICARBONATE	8MDF5V39QO	ACTIB
POTASSIUM CHLORIDE	660YQ98I10	ACTIB
WATER	059QF0KO0R	IACT
CARBON DIOXIDE	142M471B3J	IACT
MAGNESIUM CHLORIDE	02F3473H9O	ACTIB
ANHYDROUS DEXTROSE	5SL0G7R0OK	ACTIB
LACTIC ACID	33X04XA5AT	ACTIB
SODIUM CHLORIDE	451W47IQ8X	ACTIB
SODIUM BICARBONATE	8MDF5V39QO	ACTIB
POTASSIUM CHLORIDE	660YQ98I10	ACTIB

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
Version	Effective date	Source	Hydrated
35	2025-03-13	full-release	2026-05-31 21:37:04

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 18 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Match
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates
Carbon Dioxide	CARBON DIOXIDE	142M471B3J	INJECTION / INTRAVENOUS	ADJ PH	Exact identifier — unii+route+dosage form 18 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 2 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 15 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N021703-001	PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2006-10-25
N021703-002	PRISMASOL BGK 2/0 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25
N021703-003	PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25
N021703-004	PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25
N021703-005	PRISMASOL BGK 4/0 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25
N021703-006	PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25
N021703-007	PRISMASOL BK 0/0 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25
N021703-008	PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25
N021703-009	PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25
N021703-010	PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2008-10-10
N021703-011	PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10
N021703-012	PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION		2008-10-10
N021703-013	PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2008-10-10
N021703-014	PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10
N021703-015	PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 17 · 645 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	N021703-001	PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-002	PRISMASOL BGK 2/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-003	PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-004	PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-005	PRISMASOL BGK 4/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-006	PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-007	PRISMASOL BK 0/0 IN PLASTIC CONTAINER	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-008	PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-009	PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-010	PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2008-10-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-011	PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-012	PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION		2008-10-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-013	PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2008-10-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-014	PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N021703-015	PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N021703-001	PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-002	PRISMASOL BGK 2/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-003	PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-004	PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-005	PRISMASOL BGK 4/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-006	PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-007	PRISMASOL BK 0/0 IN PLASTIC CONTAINER	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-008	PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-009	PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-010	PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2008-10-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-011	PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-012	PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION		2008-10-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-013	PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2008-10-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-014	PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N021703-015	PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2008-10-10	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N021703-001	PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-002	PRISMASOL BGK 2/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-003	PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-004	PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-005	PRISMASOL BGK 4/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-006	PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-007	PRISMASOL BK 0/0 IN PLASTIC CONTAINER	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-008	PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-009	PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	INJECTABLE / INJECTION		2006-10-25	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021703-010	PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD	2008-10-10	`011fe1cb6892…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION		RLD, RS	2015-01-13
N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION		RLD, RS	2015-01-13

Observed Orange Book product history#

Product history page 1 of 3 · 86 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`8072bd15b7f6…`
2024-05-31 18:47 UTC	2024-05	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`8072bd15b7f6…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N207026-001	PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N207026-002	PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	INJECTABLE / INJECTION	RLD, RS	2015-01-13	`74a2ff9319b5…`

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Exclusivity code	Expiration	Source SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N207026-001	ODE-85	2022-01-13	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N207026-002	ODE-85	2022-01-13	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N207026-001	ODE-85	2022-01-13	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N207026-002	ODE-85	2022-01-13	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N207026-001	ODE-85	2022-01-13	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N207026-002	ODE-85	2022-01-13	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N207026-001	ODE-85	2022-01-13	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N207026-002	ODE-85	2022-01-13	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	N207026-001	ODE-85	2022-01-13	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	N207026-002	ODE-85	2022-01-13	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N207026-001	ODE-85	2022-01-13	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	N207026-002	ODE-85	2022-01-13	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N207026-001	ODE-85	2022-01-13	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N207026-002	ODE-85	2022-01-13	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N207026-001	ODE-85	2022-01-13	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	N207026-002	ODE-85	2022-01-13	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N207026-001	ODE-85	2022-01-13	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N207026-002	ODE-85	2022-01-13	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N207026-001	ODE-85	2022-01-13	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N207026-002	ODE-85	2022-01-13	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	N207026-001	ODE-85	2022-01-13	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N207026-002	ODE-85	2022-01-13	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N207026-001	ODE-85	2022-01-13	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N207026-002	ODE-85	2022-01-13	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N207026-001	ODE-85	2022-01-13	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N207026-002	ODE-85	2022-01-13	`ea99ee380514…`
2023-01-26 05:58 UTC	2023-01	N207026-001	ODE-85	2022-01-13	`3bdfa0b2c4d7…`
2023-01-26 05:58 UTC	2023-01	N207026-002	ODE-85	2022-01-13	`3bdfa0b2c4d7…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	N207026-001	ODE-85	2022-01-13	`3a93d1ddd44b…`
2022-11-12 20:34 UTC · 5 captures of this ZIP	2022-11	N207026-002	ODE-85	2022-01-13	`3a93d1ddd44b…`
2022-10-28 04:53 UTC	2022-10	N207026-001	ODE-85	2022-01-13	`f41ea6bd6efb…`
2022-10-28 04:53 UTC	2022-10	N207026-002	ODE-85	2022-01-13	`f41ea6bd6efb…`
2022-09-29 23:25 UTC	2022-09	N207026-001	ODE-85	2022-01-13	`e64feba35796…`
2022-09-29 23:25 UTC	2022-09	N207026-002	ODE-85	2022-01-13	`e64feba35796…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N207026-001	ODE-85	2022-01-13	`cb3db0bc1861…`
2022-07-09 03:26 UTC · 3 captures of this ZIP	2022-07	N207026-002	ODE-85	2022-01-13	`cb3db0bc1861…`

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
PRISMASOL BGK2/0	MAGNESIUM CHLORIDE, DEXTROSE ANHYDROUS, LACTIC ACID, SODIUM CHLORIDE, SODIUM BICARBONATE, AND POTASSIUM CHLORIDE	Vantive US Healthcare LLC	7f675fee-8940-4ece-bb0c-75ac79d8708c	2025-05-31	Warnings, Adverse reactions	Exact identifier ndc (package): 24571-108-06 ndc (package): 24571-102-06 ndc (package): 24571-113-06 ndc (package): 24571-114-06 ndc (package): 24571-117-06 ndc (package): 24571-103-06 ndc (package): 24571-116-06 ndc (package): 24571-111-06 ndc (package): 24571-105-06 ndc (product): 24571-117 ndc (product): 24571-116 ndc (product): 24571-114 ndc (product): 24571-111 ndc (product): 24571-103 ndc (product): 24571-113 ndc (product): 24571-108 ndc (product): 24571-102 ndc (product): 24571-105 ndc11 (package): 24571011306 ndc11 (package): 24571011706 ndc11 (package): 24571010506 ndc11 (package): 24571011106 ndc11 (package): 24571010306 ndc11 (package): 24571011406 ndc11 (package): 24571011606 ndc11 (package): 24571010206 ndc11 (package): 24571010806 spl id: 3744e93f-f360-485a-bad4-948c168127c2 spl set id: 7f675fee-8940-4ece-bb0c-75ac79d8708c

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.